Elevated levels of IgA antibodies against dopamine 2 receptors were observed in COVID-19 patients regardless of severity of the clinical disease, which might be explained by the chemotaxis of lymphocytes to the target organs, and respiratory and digestive systems, which are abundant with diverse IgA antibodies. This evidence concerns the gene CD79A and COVID-19.